phenmetrazine (preludin) Report issue

Small molecule Approved FDA
ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Phenmetrazine is an anti-obesity drug, which was discovered by Boehringer-Ingelheim in 1952 and approved by FDA under the name Preludin. Later on the drug was withdrawn from the market due to the reported cases of abuse. According to some studies, misuse of phenmetrazine turned many young addicts to crime. It is suggested that the drug exerts its effect by inhibiting the monoamine transport.   NCATS

Chemistry

More Chemistry

Pharmacology

Alternative names

2-phenyl-3-methylmorpholine | 3-methyl-2-phenylmorpholine | 3-methyl-2-phenyltetrahydro-2h-1,4-oxazine | fenmetrazin | fenmetrazina | fenmetrazine | oxazimedrine | phenmetraline hcl | phenmetrazin | phenmetrazine | phenmetrazine chloride | phenmetrazine hcl | phenmetrazine hydrochloride | phenmetrazine teoclate | phenmetrazinum | preludin

Organizations (1)

Research & Development (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (1)

Approved Indications (1)


 

Obesity

Experimental Indications - Clinical Trial Phases 1-4 (0)

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue